Avaliação in vitro do potencial antifúngico de sais imidazólicos frente a Candida albicans

Aim: This study aims to evaluate the antifungal potential of imidazolium salts (IS) against Candida albicans. Material and methods: Antifungal evaluation of the IS was performed using the disk diffusion test, using a strain of Candida albicans (ATCC 90028). Five different IS were synthesized and tested in the present study: 1,8-bis(methylimidazolium-1-yl) octane bromide (MImC8MImBr2), 1,12-bis(methylimidazolium-1-yl) dodecane methanesulfonate (MImC12MIm(MeS)2), 1-n-hexadecyl-2,3-dimethylimidazolium chloride (C16DMImCl), 1,10-bis(methylimidazolium-1-yl) decane methanesulfonate (MImC10MIm(MeS)2) e 1,10-bis(methylimidazolium-1-yl) decane bromide (MImC10MImBr2). Cetylpyridinium chloride (C16PyrCl) was used as a reference substance. Chlorhexidine (C34H54Cl2N10O14) and saline (NaCl 0,9%) solutions were positive and negative controls, respectively. Results: Among the tested IS, MImC12MIm(MeS)2, MImC10MIm(MeS)2 and MImC10MImBr2 showed the following values for inhibition halos: 28,00 mm, 20,50 mm and 18,75 mm, respectively. These values were similar or superior than those found for the positive control (14.87 mm) and reference (0 mm) substances. Discussion: IS can be a promising alternative to antifungal conventional therapies, as exemplified in previous studies. However, further in vitro and in vivo studies are needed to assess the antifungal potential of these compounds against Candida-mixed biofilms. Conclusion: Based on these results, there are three in vitro promising antifungal potential against Candida albicans IS tested in this study.Objetivo: O objetivo deste estudo foi avaliar o potencial antifúngico de um conjunto de sais imidazólicos (SI) frente a Candida albicans. Materiais e métodos: A avaliação antifúngica dos SI foi realizada por meio do teste de difusão em ágar, utilizando uma cepa de Candida albicans (ATCC 90028). Cinco diferentes SI foram sintetizados e testados no presente estudo: brometo de 1,8-bis(metilimidazólio-1-il) octano (MImC8MImBr2), metanossulfonato de 1,12-bis(metilimidazólio-1-il) dodecano (MImC12MIm(MeS)2), cloreto de 1-n-hexadecil-2,3-dimetilimidazólio (C16DMImCl), metanossulfonato de 1,10-bis(metilimidazólio-1-il) decano (MImC10MIm(MeS)2) e brometo de 1,10-bis(metilimidazólio-1-il) decano (MImC10MImBr2). O cloreto de cetilpiridíneo (C16PyrCl) foi utilizado como composto de referência e as soluções de digluconato de clorexidina (C34H54Cl2N10O14) e salina (NaCl 0,9%) foram utilizadas como controles positivo e negativo, respectivamente. Resultados: Dentre os SI testados, MImC12MIm(MeS)2, MImC10MIm(MeS)2 e MImC10MImBr2 apresentaram os seguintes valores para os halos de inibição formados: 28,00 mm, 20,50 mm e 18,75 mm, respectivamente. Esses valores foram similares ou superiores inclusive aos encontrados para o controle positivo (14,87 mm) e o composto de referência (0 mm). Discussão: Os SI podem apresentar uma alternativa promissora às terapias com antifúngicos convencionais, concordando com estudos prévios. Entretanto, mais estudos in vitro e in vivo são necessários para avaliar o potencial antifúngico destes compostos frente a biofilmes multiespécies de C. albicans. Conclusão: Baseado nestes resultados, três dos SI testados apresentam atividade antifúngica in vitro promissora frente à Candida albicans

The 13th Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the SDSS-IV Survey Mapping Nearby Galaxies at Apache Point Observatory

The fourth generation of the Sloan Digital Sky Survey (SDSS-IV) began observations in July 2014. It pursues three core programs: APOGEE-2,MaNGA, and eBOSS. In addition, eBOSS contains two major subprograms: TDSS and SPIDERS. This paper describes the first data release from SDSS-IV, Data Release 13 (DR13), which contains new data, reanalysis of existing data sets and, like all SDSS data releases, is inclusive of previously released data. DR13 makes publicly available 1390 spatially resolved integral field unit observations of nearby galaxies from MaNGA,the first data released from this survey. It includes new observations from eBOSS, completing SEQUELS. In addition to targeting galaxies and quasars, SEQUELS also targeted variability-selected objects from TDSS and X-ray selected objects from SPIDERS. DR13 includes new reductions ofthe SDSS-III BOSS data, improving the spectrophotometric calibration and redshift classification. DR13 releases new reductions of the APOGEE-1data from SDSS-III, with abundances of elements not previously included and improved stellar parameters for dwarf stars and cooler stars. For the SDSS imaging data, DR13 provides new, more robust and precise photometric calibrations. Several value-added catalogs are being released in tandem with DR13, in particular target catalogs relevant for eBOSS, TDSS, and SPIDERS, and an updated red-clump catalog for APOGEE.This paper describes the location and format of the data now publicly available, as well as providing references to the important technical papers that describe the targeting, observing, and data reduction. The SDSS website, http://www.sdss.org, provides links to the data, tutorials and examples of data access, and extensive documentation of the reduction and analysis procedures. DR13 is the first of a scheduled set that will contain new data and analyses from the planned ~6-year operations of SDSS-IV.PostprintPeer reviewe

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries